TNF-á inhibitor etanercept and hematologic malignancies: Report of a case and review of the literature

Bijay Nair, Girindra Raval, Paulette Mehta

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations

Abstract

We report here a 57-year-old man treated with etanercept for 6 months for psoriasis who developed myelodysplasia with acute myeloid leukemia. Leukemia cells had distinct karyotype associated with poor prognosis. The patient did not respond to cytosine arabinoside 100 mg/m2 continuous infusion over 7 days with daunorubicin 45 mg/m2 daily for 3 days. He also did not respond to salvage induction therapy with gemtuzumab (6 mg/m2 on day 1 and 4 mg/m2 on day 8) and intravenous continuous infusion cytosine arabinoside 200 mg/m2. We review other cases of lymphoma and leukemia associated with tumor necrosis factor inhibitors and suggest mechanisms by which inhibition of the TNF-α family may predispose to cancer. We also suggest that all patients being considered for TNF-α treatment be screened for hematologic malignancies or premalignancies with blood counts and bone marrow aspirates/biopsies if indicated.

Original languageEnglish (US)
Pages (from-to)1022-1024
Number of pages3
JournalAmerican Journal of Hematology
Volume82
Issue number11
DOIs
StatePublished - Nov 2007
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'TNF-á inhibitor etanercept and hematologic malignancies: Report of a case and review of the literature'. Together they form a unique fingerprint.

Cite this